###begin article-title 0
###xml 6 23 6 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 62 67 <span type="species:ncbi:9606">woman</span>
A new CYP21A1P/CYP21A2 chimeric gene identified in an Italian woman suffering from classical congenital adrenal hyperplasia form
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 117 127 117 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">(CYP21A2) </italic>
###xml 306 315 306 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 330 337 330 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2</italic>
###xml 377 394 377 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 495 512 495 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 521 525 521 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6</italic>
###xml 551 558 <span type="species:ncbi:9606">patient</span>
More than 90% of Congenital Adrenal Hyperplasia (CAH) cases are associated with mutations in the 21-hydroxylase gene (CYP21A2) in the HLA class III area on the short arm of chromosome 6p21.3. In this region, a 30 kb deletion produces a non functional chimeric gene with its 5' and 3' ends corresponding to CYP21A1P pseudogene and CYP21A2, respectively. To date, five different CYP21A1P/CYP21A2 chimeric genes have been found and characterized in recent studies. In this paper, we describe a new CYP21A1P/CYP21A2 chimera (CH-6) found in an Italian CAH patient.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 118 123 118 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 68 75 <span type="species:ncbi:9606">patient</span>
Southern blot analysis and CYP21A2 sequencing were performed on the patient. In addition, in order to isolate the new CH-6 chimeric gene, two different strategies were used.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 420 437 420 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 452 456 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6</italic>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 48 55 <span type="species:ncbi:9606">patient</span>
###xml 350 355 <span type="species:ncbi:9606">woman</span>
The CYP21A2 sequencing analysis showed that the patient was homozygote for the g.655C/A>G mutation and heterozygote for the p.P30L missense mutation. In addition, the promoter sequence revealed the presence, in heterozygosis, of 13 SNPs generally produced by microconversion events between gene and pseudogene. Southern blot analysis showed that the woman was heterozygote for the classic 30-kb deletion producing a new CYP21A1P/CYP21A2 chimeric gene (CH-6). The hybrid junction site was located between the end of intron 2 pseudogene, after the g.656C/A>G mutation, and the beginning of exon 3, before the 8 bp deletion. Consequently, CH-6 carries three mutations: the weak pseudogene promoter region, the p.P30L and the g.655C/A>G splice mutation.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 18 35 18 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6</italic>
###xml 119 126 <span type="species:ncbi:9606">patient</span>
We describe a new CYP21A1P/CYP21A2 chimera (CH-6), associated with the HLA-B15, DR13 haplotype, in a young Italian CAH patient.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 133 140 133 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2</italic>
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder mainly caused by defects in the steroid 21-hydroxylase gene (CYP21A2). Steroid 21-hydroxylase is a microsomal cytochrome P450 required for the synthesis of cortisol and aldosterone but not for the synthesis of sex steroids. The reduced synthesis of cortisol and aldosterone leads to excessive androgen production [1].
###end p 11
###begin p 12
###xml 124 125 124 125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 338 339 338 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 128 136 <span type="species:ncbi:9606">Patients</span>
CAH includes a wide spectrum of clinical manifestations. Milder forms are referred to as Nonclassic (NC) or late-onset CAH [2]. Patients with the severe classic disease form are classified as either salt-wasting (SW) or simple-virilising (SV) depending on whether or not synthesis of the salt retaining hormone, aldosterone, is affected [3].
###end p 12
###begin p 13
###xml 34 41 34 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2</italic>
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 196 198 196 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RP</italic>
###xml 211 213 211 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C4</italic>
###xml 238 243 238 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21</italic>
###xml 258 262 258 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNX </italic>
###xml 457 499 457 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RP1-C4A-CYP21A1P-TNXA-RP2-C4B-CYP21A2-TNXB</italic>
###xml 524 538 524 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P-TNXA </italic>
###xml 542 545 542 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RP2</italic>
###xml 615 616 615 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 617 618 617 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
The gene encoding 21-hydroxylase, CYP21A2, is located in the HLA class III region on the short arm of chromosome 6p21.3 [4]. In this region, four tandemly arranged genes - serine/threonine Kinase RP, complement C4, steroid 21-hydroxylase CYP21, and tenascin TNX - are organized as a genetic unit designated as a RCCX module. In a RCCX bimodular haplotype, duplication of the RCCX module occurs and the orientation of genes, from telomere to centromere, is: RP1-C4A-CYP21A1P-TNXA-RP2-C4B-CYP21A2-TNXB. The three pseudogenes, CYP21A1P-TNXA and RP2, located between the two C4 loci, do not encode functional proteins [5,6].
###end p 13
###begin p 14
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 210 218 210 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 227 236 227 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 589 590 589 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 789 791 789 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 833 841 833 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 859 876 859 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 1004 1012 1004 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P</italic>
###xml 1025 1029 1025 1029 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C4B </italic>
###xml 1053 1060 1053 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2</italic>
###xml 1150 1159 1150 1159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 1163 1170 1163 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2</italic>
###xml 1186 1187 1186 1187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1188 1190 1188 1190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1226 1243 1226 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 1302 1304 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1305 1307 1305 1307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1343 1360 1343 1360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 1375 1379 1375 1379 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6</italic>
###xml 1401 1408 <span type="species:ncbi:9606">patient</span>
In the Caucasian population, bimodular and monomodular RCCX organizations are present in about 69% and 17% of chromosome 6, respectively, while trimodular RCCX haplotypes have a frequency of about 14% [7]. The CYP21A2 gene and CYP21A1P pseudogene each contain 10 exons spaced over 3.1 Kb, their nucleotide sequences are 98% identical in exons and approximately 96% identical in introns [8]. Intergenic recombinations are responsible for 95% of the mutations associated with 21-hydroxylase deficiency; the remaining 5% of mutations do not appear to be the result of gene conversion events [9,10]. Among the intergenic recombinations, approximately 75% is represented by mutations normally present in the pseudogene and possibly transferred to the functional gene by microconversion events [11]. The remaining 20%-25% of mutations are CYP21A2 gene deletions or CYP21A1P/CYP21A2 chimeric genes. In fact, the 26 or 32 Kb deletion (depending on whether C4B is the long or short gene), involving the 3' end of CYP21A1P, all of the C4B gene, and the 5' end of CYP21A2, produces a single non functional chimeric gene with its 5' and 3' ends corresponding to CYP21A1P and CYP21A2, respectively [1,11]. To date, five different chimeric CYP21A1P/CYP21A2 genes have been found and characterized in recent studies [12-16]. In this paper, we describe a new CYP21A1P/CYP21A2 chimeric gene (CH-6) found in an Italian patient suffering from a severe form of CAH.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 16
###begin p 17
###xml 673 676 673 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 4 11 <span type="species:ncbi:9606">patient</span>
The patient is the first daughter of non consanguineous parents of Italian origin. No family history of CAH, of virilisation in female family members or of impaired fertility was reported. Pregnancy and delivery were uneventful and birth weight and length were normal (3400 g, 51 cm). Diagnosis of CAH was suspected due to genital virilisation (Prader IV). Thus, hormonal evaluation and kariotype were requested. Plasma levels of Na and K were 124 mEq/L and 6.2 mEq/L, respectively, while 17-OHP plasma value, on fourth day of life, was 223 nmol/L. Kariotype showed a normal female pattern (46, XX). Therapy with betamethasone and fluorohydrocortisone was started on the 11th day. No vomiting or other clinical signs of salt wasting were shown before onset of substitutive therapy.
###end p 17
###begin p 18
###xml 95 102 <span type="species:ncbi:9606">patient</span>
Clitoromegaly was corrected at 4 yr of age and hydrocortisone therapy was started at 6 yr. The patient showed a normal pubertal development with menarche at 14 yr and she underwent vaginoplasty at 17 yr. She married at 26 yr with a healthy Italian male and she was pregnant at 29 yr.
###end p 18
###begin title 19
Molecular analysis of CYP21A2 gene
###end title 19
###begin p 20
Informed consent for genetic study was obtained, it was in compliance with the Helsinki Declaration and was approved by Catholic University Ethics Committee (Reference Number: P6242008).
###end p 20
###begin p 21
###xml 277 280 271 274 <sup xmlns:xlink="http://www.w3.org/1999/xlink">th </sup>
###xml 228 235 <span type="species:ncbi:9606">patient</span>
Genomic DNA was isolated from peripheral blood samples using High Pure PCR Template Preparation Kits (Roche Diagnostic, USA), quantified by spectrophotometer at 260 nm and stored at -20degreesC until use. In addition, since the patient decided to undergo an amniocentesis at 18th week of gestation, a DNA sample was extracted from amniotic fluid cells.
###end p 21
###begin p 22
###xml 125 133 125 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 237 245 237 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
Two genomic DNA fragments, spanning from the 5' region to exon 6 (FRAG 1) and from exon 6 to 3'region (FRAG 2) of the active CYP21A2 gene, were amplified using two sets of specific primers, as previously described [17]. In addition, the CYP21A2 promoter region was amplified using the primers: PROM-F 5'-gca ggg act gcc att ttc tc-3' (nucleotides 87034-87053; GeneBank accession ) and PROM-R 5'-agc agg gag tag tct ccc aag-3'(nucleotides 85935-85955; GeneBank accession ).
###end p 22
###begin p 23
PCR-amplified fragments were directly sequenced using BigDye Terminator Cycle Sequencing kit v3.1(Applied Biosystems, USA) and ABI 3100 Avant Genetic Analyser (Applied Biosystems, USA) according to manufacturer's instructions.
###end p 23
###begin p 24
###xml 98 106 98 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
The results were analysed using the SeqScape v2.5 software package (Applied Biosystems, USA). The CYP21A2 sequence references were: NCBI-AL049547 and NC-000006.
###end p 24
###begin title 25
HLA typing
###end title 25
###begin p 26
HLA-B and HLA-DRB1 genotypes were determined using a semi-automated, commercially available reverse dot-blot method (Inno-lipa, Innogenetics, Gent, Belgium), according to the manufacturer's instructions. Reaction patterns were interpreted using INNO-LiPA software.
###end p 26
###begin title 27
CYP21/C4 haplotyping
###end title 27
###begin p 28
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 340 348 340 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Leukocyte DNA was digested with TaqI restriction enzyme and Southern blotting studies were conducted as previously described [18]. Blots were probed with a mixture of two fragments: a 500-bp BamHI-KpnI 5' fragment of C4 cDNA (pAT-A clone) and a 3.1-Kb genomic EcoRI-BamHI fragment of the 5.5-Kb BglII-BamHI fragment encompassing the entire CYP21A2 gene cloned in the BamHI site of bluscript SK+ plasmid [18,19].
###end p 28
###begin p 29
Band ratios were measured by laser densitometry (Ultroscan XL laser densitometer; Pharmacia LKB).
###end p 29
###begin title 30
Isolation of CYP21A1P/CYP21A2 chimeric gene
###end title 30
###begin p 31
###xml 33 50 33 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 381 390 381 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 476 484 476 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
In order to isolate the chimeric CYP21A1P/CYP21A2 allele, two different strategies were used. The first was an allele specific PCR performed using the primers: PROMPS 5'-cca ggt cgg ggc gga cac cc-3' (nucleotides 433-452; GeneBank accession  [region: 32.080.697...32.084.739]) and PROM-R (nucleotides 85935-85955; GeneBank accession ). The PROMPS forward primer was specific for a CYP21A1P pseudogene 5' sequence while the reverse PROM-R primer was specific for exon 3 of the CYP21A2 active gene. The PCR fragment, spanning from the 5' region to exon 3 of the chimeric gene, was directly sequenced.
###end p 31
###begin p 32
###xml 187 195 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNXB </italic>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 528 536 522 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 558 575 552 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 595 597 589 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 640 657 634 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 786 795 780 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 876 881 870 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink">TNXB </italic>
The second strategy was the amplification (Expand Long Template PCR System, Roche Diagnostic, USA), using CYP779f and Tena36F2 primers, of a 6.2Kb fragment encompassing the 5'-end of the CYP21A2 gene and exon 36 of the TNXB gene [20]. After amplification, 700 ng of the PCR product was incubated at 65degreesC for 2 h with 10 U of Taq I restriction enzyme. The completely digested PCR product was analyzed by electrophoresis on a 1.2% agarose gel to evaluate the presence of the 3.7- and 3.2-Kb fragments produced by the active CYP21A2 gene and the chimeric CYP21A1P/CYP21A2 gene, respectively [20]. The 3.2 Kb fragment including the whole CYP21A1P/CYP21A2 chimera [being generated by the Taq I cutting at 86870 position (GeneBank accession ), corresponding to -209 C nucleotide in the CYP21A1P promoter region, and at 83662 position (GeneBank accession ) within 5' region of TNXB gene] was isolated from agarose gel (QIAEX II Gel Extraction Kit, Qiagen, Hilden, Germany) and sequenced using internal primers (available on request). In order to confirm the obtained results the 6.2 kb fragment was cloned into the pGEM-T vector system (Promega, Madison, WI, USA) and the identified clone was directly used as template for DNA sequencing.
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Molecular analysis of CYP21A2 gene
###end title 34
###begin p 35
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 48 55 <span type="species:ncbi:9606">patient</span>
The CYP21A2 sequencing analysis showed that the patient was homozygote for the g.655C/A>G mutation in intron 2 and heterozygote for the p.P30L missense mutation in exon 1. In addition, the promoter sequence revealed the presence, in heterozygosis, of 13 variants (g.-306G>C, g.-295T>C, g.-294A>C, g.-283A>G, g.-281T>G, g.-210T>C, g.-199C>T, g.-190insT, g.-126C>T, g.-113G>A, g.-110T>C, g.-103A>G and g.-4C>T) which are generally the result of microconversion events between gene and pseudogene. In this first sequencing analysis step, we were unable to perform the complete nucleotide analysis of intron 2 since the electropherogram showed various frameshift mutations resulting in two overlapping sequences.
###end p 35
###begin p 36
###xml 44 52 44 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
The same problem was present when the fetus'CYP21A2 sequence was analyzed. However, the results showed that the fetus' DNA carried, in heterozigiosis, both the g.656C/A>G and p.P30L mutations in addition to the 13 variants in the promoter region.
###end p 36
###begin p 37
###xml 58 66 58 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 13 20 <span type="species:ncbi:9606">patient</span>
Finally, the patient's husband resulted wild type for the CYP21A2 sequencing analysis.
###end p 37
###begin title 38
HLA typing
###end title 38
###begin p 39
###xml 60 67 <span type="species:ncbi:9606">patient</span>
The results of HLA-DRB and HLA-B genotypes were as follows: patient: HLA-B*35/44 HLA-DRB1*01/13; husband: HLA-B*15/51 HLA-DRB1*11/13; male fetus: HLA-B*15/44 HLA-DRB1*01/13. These results confirmed the correct segregation of HLA loci.
###end p 39
###begin title 40
CYP21/C4 haplotyping
###end title 40
###begin p 41
###xml 44 45 44 45 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 163 171 163 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 208 217 208 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 430 438 430 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 448 457 448 457 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 762 770 762 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 812 821 812 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 962 965 962 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C4 </italic>
###xml 353 360 <span type="species:ncbi:9606">patient</span>
The Southern blot results are shown in Fig. 1 and were interpreted as follows: 1) the fetus' father (lane 1) carried two bimodular chromosomes with a total of two CYP21A2 genes (3.7 kb and 2.5 kb bands), two CYP21A1P pseudogenes (3.2 kb and 2.4 kb bands), two long telomeric C4 genes(7.0 kb band) and two short non-telomeric C4 genes (5.4 kb band); the patient (lane 2) carried a chromosome with a normal bimodular structure (one CYP21A2 gene, one CYP21A1P pseudogene, one long telomeric C4 gene and one long non-telomeric C4 gene corresponding to 6.4 kb band) and a chromosome with the classic 30 Kb deletion (as shown by decreased intensities of 6.4 kb band, corresponding to the C4B gene, and of 3.7 kb and 2.4 kb bands corresponding to the 5' section of the CYP21A2 active gene and to the 3' fragment of the CYP21A1P pseudogene, respectively); finally, the fetus (lane 3) inherited from the father a wild type bimodular chromosome with a short non-telomeric C4 gene and from the mother the chromosome with the 30 kb deletion (as shown by the absence of the 6.4 kb band and by the decreased intensities of 3.7 kb and 2.4 kb bands).
###end p 41
###begin p 42
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Southern blot analysis</bold>
###xml 97 105 97 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C4 </italic>
Southern blot analysis. Taq I restriction patterns of genomic DNA hybridized to a mixture of the CYP21A2 and C4 cDNA probes. Fa: father, Mo: mother. For pattern analysis see the text in results section.
###end p 42
###begin title 43
Sequence of CYP21A1P/CYP21A2 chimeric gene
###end title 43
###begin p 44
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 208 213 208 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 225 239 225 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P-like </italic>
###xml 331 339 331 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
The 6.2 Kb long PCR digested with TaqI enzyme[20] combined with cloning and sequencing of 3.2 Kb fragment allowed to prove the existence of the new chimeric gene. In fact, the sequencing analysis showed that CH-6 gene have a CYP21A1P-like sequence up to 656 nucleotide of intron 2 while the remaining exons/intons have a wild type CYP21A2 sequence (Fig. 2).
###end p 44
###begin p 45
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequence of the new chimeric gene</bold>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 207 215 207 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 234 242 234 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 276 285 276 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 384 393 384 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 396 401 396 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 405 413 405 413 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 470 478 470 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
Sequence of the new chimeric gene. Sequence of CH-6 chimera from +1 nucleotide (exon 1) to +721 nucleotide (exon 3). Nucleotides were numbered starting from ATG. The lines showed: the amino acid sequence of CYP21A2 gene (M13936), the CYP21A2 nucleotide sequence (M13936), the CYP21A1P nucleotide sequence (M13935) and the CH-6 nucleotide sequence. Only nucleotide differences between CYP21A1P or CH-6 and CYP21A2 active gene are shown under corresponding nucleotides in CYP21A2 gene.
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 13 30 13 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 105 107 105 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XA</italic>
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RP2</italic>
###xml 118 122 118 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C4B </italic>
###xml 157 166 157 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 170 178 170 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
The chimeric CYP21A1P/CYP21A2 gene is the consequence of the 26 or 32 Kb deletion including the complete XA, RP2, and C4B genes and the partial sequences of CYP21A1P and CYP21A2 genes [20].
###end p 47
###begin p 48
###xml 91 94 91 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Chi</italic>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 254 257 254 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">chi</italic>
###xml 332 340 332 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 344 353 344 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 414 455 414 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">RP1-C4A-CYP21A1P-XA-RP2-C4B-CYP21A2-TNXB </italic>
###xml 630 632 630 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
The possible cause of the chimera formation is the presence of specific sequences, such as Chi-like and tandem-repetitive minisatellite consensus, which play a role in promoting genetic recombination [21]. In particular, it has been pointed out that the chi-like sequence GCTGGGG is present several times in the intronic regions of CYP21A2 and CYP21A1P genes [22]. However, the high degree of sequence homology of RP1-C4A-CYP21A1P-XA-RP2-C4B-CYP21A2-TNXB genes arranged in tandem, seems to be the most probable way to increase the chance of misalignment at meiosis to generate genetic recombination in the 6p21.3 chromosome area [23].
###end p 48
###begin p 49
###xml 33 50 33 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 94 96 94 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 104 105 104 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 170 174 170 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-1</italic>
###xml 176 180 176 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-2</italic>
###xml 186 191 186 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-3 </italic>
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
To date, five different chimeric CYP21A1P/CYP21A2 genes have been found and characterized [12-16] (Fig. 3). Three of them, found in ethnic Chinese (Taiwanese), are named CH-1, CH-2, and CH-3 [12-14]. In these molecules, the deletion g.707-724delGAGACTAC in exon 3 leads to a frameshift mutation which forms a TGA stop codon downstream 830 nucleotide producing a truncated protein.
###end p 49
###begin p 50
###xml 0 17 0 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 0 31 0 31 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CYP21A1P/CYP21A2 </italic>chimeric genes</bold>
###xml 33 62 33 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-1, CH-2, CH-3, CH-4, CH-5 </italic>
###xml 66 71 66 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 103 120 103 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 209 218 209 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P </italic>
###xml 237 245 237 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
CYP21A1P/CYP21A2 chimeric genes. CH-1, CH-2, CH-3, CH-4, CH-5 and CH-6 represent six distinct chimeric CYP21A1P/CYP21A2 genes as described in the text. The black and white regions represent the non-functional CYP21A1P and the functional CYP21A2 sequences, respectively. The eight nucleotide deletion in exon 3 is marked by an asterisk.
###end p 50
###begin p 51
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-4 </italic>
###xml 54 56 54 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 126 128 126 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 131 136 131 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-4 </italic>
###xml 440 445 440 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-5 </italic>
###xml 529 531 529 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 45 52 <span type="species:ncbi:9606">patient</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
CH-4 chimera was found in a Caucasian NC-CAH patient [15] and it is probably the same one earlier reported by Killeen et al. [24]. CH-4 junction site was located between the end of exon 1 and the beginning of intron 2, consequently, the resulting hybrid gene differs from the functional gene only for the presence of two deleterious mutations: the weak promoter region of the pseudogene and the p.P30L missense mutation in exon 1. Finally, CH-5 chimera, associated with the HLA-B47, DR7 haplotype, was described by White et al. [16] and results very common among CAH patients of Caucasian origin.
###end p 51
###begin p 52
###xml 31 48 31 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6</italic>
###xml 307 312 307 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 487 495 487 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 775 780 775 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6 </italic>
###xml 83 88 <span type="species:ncbi:9606">woman</span>
###xml 462 469 <span type="species:ncbi:9606">patient</span>
###xml 749 756 <span type="species:ncbi:9606">patient</span>
In this paper, we report a new CYP21A1P/CYP21A2 chimera (CH-6) found in an Italian woman suffering from salt-wasting form of CAH. The hybrid junction site was located between the end of intron 2 pseudogene, after the g.656C/A>G mutation, and the beginning of exon 3, before the 8 bp deletion. Consequently, CH-6 carries three mutations: the weak pseudogene promoter region, the p.P30L in exon 1 and the g.655C/A>G splice mutation in intron 2 (Fig. 3). Since the patient carried a second CYP21A2 allele with the g.656C/A>G mutation, her clinical severe phenotype was determined by the homozygote status for this mutation. Unfortunately, it was not possible to perform a more extensive familiar genetic study and therefore we can not determine if the patient inherited the new CH-6 chimeric gene from one of her parents.
###end p 52
###begin p 53
###xml 132 140 132 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
However, our molecular CAH prenatal diagnosis showed that the fetus inherited the new chimeric gene from his mother and a wild type CYP21A2 allele from his father, as also confirmed by HLA typing.
###end p 53
###begin title 54
Conclusion
###end title 54
###begin p 55
###xml 33 50 33 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P/CYP21A2 </italic>
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CH-6</italic>
###xml 134 141 <span type="species:ncbi:9606">patient</span>
In conclusion, we describe a new CYP21A1P/CYP21A2 chimera (CH-6), associated with the HLA-B15, DR13 haplotype, in a young Italian CAH patient.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
The authors declare that they have no competing interests.
###end p 57
###begin p 58
The study was carried out by means of funding of Institute of Biochemistry and Clinical Biochemistry, Catholic University of Rome.
###end p 58
###begin title 59
Authors' contributions
###end title 59
###begin p 60
PC carried out the molecular genetics studies, participated in the sequence alignment and drafted the manuscript.
###end p 60
###begin p 61
EM participated in the molecular genetics study and in the sequence alignment.
###end p 61
###begin p 62
AM participated in the molecular genetics studies and in the sequence alignment.
###end p 62
###begin p 63
EG participated in the molecular genetic studies.
###end p 63
###begin p 64
CZ participated in the design of the study and in its coordination.
###end p 64
###begin p 65
VT performed clinical study and participated in the design of the study and in its coordination.
###end p 65
###begin p 66
EC participated in the design of the study and drafted the manuscript.
###end p 66
###begin p 67
All authors read and approved the final manuscript.
###end p 67
###begin title 68
Pre-publication history
###end title 68
###begin p 69
The pre-publication history for this paper can be accessed here:
###end p 69
###begin p 70

###end p 70
###begin title 71
Acknowledgements
###end title 71
###begin p 72
###xml 38 46 <span type="species:ncbi:9606">patients</span>
Written consent was obtained from the patients and their relative for publication of study.
###end p 72
###begin article-title 73
Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
###end article-title 73
###begin article-title 74
Nonclassic adrenal hyperplasia
###end article-title 74
###begin article-title 75
Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults
###end article-title 75
###begin article-title 76
###xml 116 119 <span type="species:ncbi:9606">man</span>
Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man
###end article-title 76
###begin article-title 77
###xml 26 31 <span type="species:ncbi:9606">human</span>
Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin TNX (the RCCX module). A mechanism for gene deletions and disease associations
###end article-title 77
###begin article-title 78
Haplotypes of the steroid 21-hydroxylase gene region encoding mild steroid 21-hydroxylase deficiency
###end article-title 78
###begin article-title 79
###xml 16 21 <span type="species:ncbi:9606">human</span>
Deficiencies of human complement component C4A and C4B and heterozygosity in length variants of RP-C4-CYP21-TNX (RCCX) modules in caucasians. The load of RCCX genetic diversity on major histocompatibility complex-associated disease
###end article-title 79
###begin article-title 80
###xml 13 18 <span type="species:ncbi:9606">human</span>
Structure of human steroid 21-hydroxylase genes
###end article-title 80
###begin article-title 81
Frequent deletion and duplication of the steroid 21-hydroxylase genes
###end article-title 81
###begin article-title 82
CYP21 mutations and congenital adrenal hyperplasia
###end article-title 82
###begin article-title 83
Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms
###end article-title 83
###begin article-title 84
The chimeric CYP21P/CYP21 gene and 21-hydroxylase deficiency
###end article-title 84
###begin article-title 85
Use of PCR-based amplification analysis as a substitute for the southern blot method for CYP21 deletion detection in congenital adrenal hyperplasia
###end article-title 85
###begin article-title 86
Deletion of the C4-CYP21 repeat module leading to the formation of a chimeric CYP21P/CYP21 gene in a 9.3-kb fragment as a cause of steroid 21-hydroxylase deficiency
###end article-title 86
###begin article-title 87
###xml 6 13 <span type="species:ncbi:9606">patient</span>
How a patient homozygous for a 30-kb deletion of the C4-CYP 21 genomic region can have a nonclassic form of 21-hydroxylase deficiency
###end article-title 87
###begin article-title 88
HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation
###end article-title 88
###begin article-title 89
Linkage between I172N mutation, a marker of 21-hydroxylase deficiency, and a single nucleotide polymorphism in Int6 of CYP21B gene: a genetic study of Sardinian family
###end article-title 89
###begin article-title 90
Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency
###end article-title 90
###begin article-title 91
###xml 46 51 <span type="species:ncbi:9606">human</span>
The structural basis of the multiple forms of human complement component C4
###end article-title 91
###begin article-title 92
###xml 17 25 17 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A2 </italic>
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 67 70 67 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq</italic>
###xml 93 101 93 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CYP21A1P</italic>
Diversity of the CYP21A2 gene: A 6.2-Kb TaqI fragment and a 3.2-Kb TaqI fragment mistaken as CYP21A1P
###end article-title 92
###begin article-title 93
###xml 13 17 13 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">chi </italic>
Structure of chi hotspots of generalized recombination
###end article-title 93
###begin article-title 94
Identification of the recombination site within the steroid 21-hydroxylase gene (CYP21) of the HLA-B47, DR7 haplotype
###end article-title 94
###begin article-title 95
Mapping of a de novo unequal crossover causing a deletion of the steroid 21-hydroxylase (CYP21A2) gene and a non-functional hybrid tenascin-X (TNXB) gene
###end article-title 95
###begin article-title 96
Molecular and endocrine characterization of a mutation involving a recombination between the steroid 21-hydroxylase functional gene and pseudogene
###end article-title 96

